This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Problems and Prospects

Morton S. Skorodin, MD

JAMA. 1986;255(23):3283-3285.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

REGULATIONS and prescribing practices dealing with long-term home and ambulatory oxygen supplementation for patients with chronic lung disease are currently in a state of flux. Clearly, the move is on to limit this modality as much as possible because of its great expense.

Changes in Oxygen Reimbursement Policy

As recently as March 1985, Petty¹ recommended the following patient selection criteria: (1) stable clinical state with optimum medical therapy, eg, bronchodilator, antibiotics, corticosteroids (if indicated), and freedom from exacerbations of bronchitis or heart failure; (2) arterial blood gas analysis conducted on at least two occasions with the subject breathing room air for at least 20 minutes; (3) room-air arterial oxygen pressure (Pao₂) consistently (three weeks or more) less than 55 mg Hg or consistently 55 to 59 mm Hg with clinical diagnosis of cor pulmonale, a hematocrit exceeding 55%, or both (entry criteria for the Nocturnal Oxygen Therapy Trial . . . [Full Text PDF of this Article]

Author Affiliations
From the Respiratory Care Department, Ambulatory Care and Medical Services, Veterans Administration Hospital, Hines, Ill; and the Department of Medicine, Stritch School of Medicine, Loyola University of Chicago, Maywood, Ill.

Footnotes
Reprint requests to Veterans Administration Hospital, Respiratory Care Department, 111H, Hines, IL 60141 (Dr Skorodin).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?